Intensity Modulated Radiotherapy (IMRT) Versus Helical Tomotherapy (HT) in Esophageal Cancer: A Comparative Analysis

Purpose/Objectives: Definitive chemoradiation is an accepted alternative treatment in the management of esophageal cancer in patients who are not candidates for surgery. The location of esophagus poses a challenge because of its close proximity to the critical organs. Various modern techniques of radiation planning offer the advantage of better dose conformality and increased sparing of organs at risk. This study aims to compare the dosimetric parameters of Intensity Modulated Radiotherapy (IMRT) and Helical Tomotherapy (HT) planning techniques in radical radiotherapy for esophageal cancer patients. Materials/Methods: A total of 38 patients of esophageal squamous cell carcinoma with clinical staging cT2-T4/N0-N2/M0 planned for definitive chemoradiation were enrolled from June 2021 till November 2022. CT simulation was done with intravenous and oral contrast, and contouring of tumor volumes and organs at risk were done according to RTOG contouring guidelines. All patients were planned for a total dose of 50.4Gy in 28 fractions. Radiation plans of IMRT and HT were generated for each patient. Dosimetric parameters of PTV D98, D2, Dmean, V95, V110, Homogeneity Index (HI) and Conformity Index (CI) were noted for both the plans. Organs at risk (OAR) parameters such as Lung (V20, V30, V5, Dmean), Heart (V25, V30, Dmean), Spinal Cord Dmax, Larynx (Dmax, Dmean) and Liver Dmean were noted. All parameters of the two different planning techniques were compared and analyzed using SPSS software v23 with paired t-test.Results: The coverage of the PTV in IMRT and HT was similar in terms of PTV V95 and PTV D98. The regions receiving more than 107% and 110% of the prescribed dose was significantly higher in IMRT compared to HT, on assessing V107, V110 and D2 (p=0.001). HI was similar in both the groups, but the CI was significantly better in HT compared to IMRT (0.9 ± 0.02 vs 1.03 ± 0.01; p=0.002). Doses to the lungs, heart and liver were similar between the two groups. IMRT had higher spinal cord (39.1 ± 3.2 vs 34.2 ± 5.5; p=0.001) and laryngeal dose (9.6 ± 5.5 vs 5.6 ± 3.7; p=0.009) compared to HT.Conclusion: HT offers better dose conformality and uniformity when compared to IMRT with lesser dose to spinal cord and larynx. As this is a dosimetric study, a larger sample size and patient follow up is essential for clinical correlation and assessment of benefit of different radiation modalities.

[1]  H. Ma,et al.  [Dosimetric comparison of the helical tomotherapy, intensity-modulated radiotherapy and volumetric-modulated arc therapy in radical radiotherapy for esophageal cancer]. , 2019, Zhonghua yi xue za zhi.

[2]  T. Mizowaki,et al.  Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma , 2018, Radiation oncology.

[3]  C. Chien,et al.  Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy , 2017, Scientific Reports.

[4]  Daniel T Chang,et al.  Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer. , 2015, International journal of radiation oncology, biology, physics.

[5]  S. Yang,et al.  Radiotherapy for Esophageal Cancer Using Simultaneous Integrated Boost Techniques: Dosimetric Comparison of Helical TomoTherapy, Volumetric-Modulated Arc Therapy (RapidArc) and Dynamic Intensity-Modulated Radiotherapy , 2013, Technology in cancer research & treatment.

[6]  Jeff Z. Y. Chen,et al.  Dosimetric comparison of helical tomotherapy, RapidArc, and a novel IMRT & Arc technique for esophageal carcinoma. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  Mike Oliver,et al.  Comparing planning time, delivery time and plan quality for IMRT, RapidArc and tomotherapy , 2009, Journal of applied clinical medical physics.

[8]  Hisao Ito,et al.  Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. , 2009, International journal of radiation oncology, biology, physics.

[9]  M. McAleer,et al.  Principles and techniques of radiation therapy for esophageal and gastroesophageal junction cancers. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  Charles S Mayo,et al.  Hybrid IMRT for treatment of cancers of the lung and esophagus. , 2008, International journal of radiation oncology, biology, physics.

[11]  R. Mohan,et al.  Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. , 2008, International journal of radiation oncology, biology, physics.

[12]  Yi-Jen Chen,et al.  Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. , 2007, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[13]  Tae Hyun Kim,et al.  Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. , 2005, Radiology.

[14]  Michael Lock,et al.  Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic review. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Robert Jeraj,et al.  Radiation characteristics of helical tomotherapy. , 2004, Medical physics.

[16]  Narikazu Boku,et al.  Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Noël,et al.  INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy , 2002 .

[18]  R. Ginsberg,et al.  INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Cooper,et al.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. , 1999, JAMA.

[20]  M. Oldham,et al.  A comparison of conventional and conformal radiotherapy of the oesophagus: work in progress. , 1998, The British journal of radiology.

[21]  J. Cooper,et al.  Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Law Chemoradiotherapy - panacea for esophageal cancer? Commentary for 'Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow-up of a prospective randomized trial (RTOG 85-01)' , 1999 .

[23]  S. Parlee,et al.  This Work Is Licensed under a Creative Commons Attribution-noncommercial 4.0 International License , 2022 .